Clinical Trial Update: A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD [Phase 2]

View source ↗

Summary

This document reports that GAL-101, a 2% ophthalmic solution developed by Galimedix Therapeutics, is being evaluated in a Phase 2 trial for non-foveal geographi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Geographic Atrophy of the Macula

Drugs mentioned

• GAL-101

Snippet

Sponsor: Galimedix Therapeutics Inc | Conditions: Geographic Atrophy of the Macula | Phase 2 | Status: RECRUITING